^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Undisclosed GPR161 modulator therapeutic

i
Other names: Undisclosed GPR161 modulator therapeutic
Associations
Trials
Company:
Omeros
Drug class:
GPR161 modulator
Associations
Trials
1year
Genomic landscape of medulloblastoma subtypes in an Asian cohort. (PubMed, Transl Cancer Res)
All germline variants of the ten susceptibility genes of interest (APC, BRCA2, PTCH1, PTCH2, ELP1, SUFU, CTNNB1, SMARCA4, GPR161, and TP53) were annotated and validated...This study provides valuable insights into the genetic landscape of MB in an Asian cohort, emphasizing the importance of population-specific research. The subtype-specific germline variant landscape identified in this study contributes to the understanding of MB and its genetic underpinnings in Asian populations, potentially guiding future research and therapeutic strategies.
Journal • BRCA Biomarker
|
TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • PTCH1 (Patched 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway)
|
Undisclosed GPR161 modulator therapeutic
over1year
Frequency of pathogenic germline variants in pediatric medulloblastoma survivors. (PubMed, Front Oncol)
Most cases are sporadic, but well characterized germline alterations in APC, ELP1, GPR161, PTCH1, SUFU, and TP53 predispose to medulloblastoma...Approximately one in eight pediatric medulloblastoma survivors had an autosomal dominant P/LP CSG variant. We confirm several known associated genes and identify novel genes that may be important in medulloblastoma.
Journal
|
TP53 (Tumor protein P53) • PTCH1 (Patched 1) • APC (APC Regulator Of WNT Signaling Pathway)
|
Undisclosed GPR161 modulator therapeutic
almost2years
The evolutionary impact of childhood cancer on the human gene pool. (PubMed, Nat Commun)
For six genes [ELP1, GPR161, VHL and SDHA/B/C], a clear lack of mutational constraint calls the pediatric penetrance and/or severity of associated cancers into question. Conversely, out of 23 known pCPS genes associated with biallelic risk, two [9%, DIS3L2 and MSH2] show significant constraint, indicating that they may monoallelically increase childhood cancer risk. In summary, we show that population genetic data provide empirical evidence that heritable childhood cancer leads to natural selection powerful enough to have significantly impacted the present-day gene pool.
Journal
|
MSH2 (MutS Homolog 2) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)
|
Undisclosed GPR161 modulator therapeutic
over2years
Perspectives on the implications of carrying putative pathogenic variants in the medulloblastoma predisposition genes ELP1 and GPR161. (PubMed, Fam Cancer)
We also screened 27 PTCH1/SUFU pathogenic variant-negative patients with Gorlin syndrome for GPR161 and found no suspicious variants. Given the population frequencies of 0.0962% for GPR161 and 0.0687% for ELP1, neither of these genes can be a cause of Gorlin syndrome with an unexplained population frequency far lower at 0.0021%.
Journal
|
PTCH1 (Patched 1)
|
Undisclosed GPR161 modulator therapeutic
almost3years
FREQUENCY OF PATHOGENIC GERMLINE VARIANTS IN PEDIATRIC MEDULLOBLASTOMA SURVIVORS (ASPHO 2023)
Most cases are sporadic, but well characterized germline alterations in APC, ELP1, GPR161, PTCH1, PTCH2, SUFU, and TP53 predispose to medulloblastoma... One-fifth of pediatric medulloblastoma survivors had a P/LP CSG variant, some in genes which had not previously been associated with medulloblastoma, and therefore need to be replicated. These findings suggest that routine germline testing for children with medulloblastoma at diagnosis should be considered.
Clinical
|
TP53 (Tumor protein P53) • PTCH1 (Patched 1) • APC (APC Regulator Of WNT Signaling Pathway) • CHEK2 (Checkpoint kinase 2) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • MRE11A (MRE11 homolog, double strand break repair nuclease)
|
Undisclosed GPR161 modulator therapeutic